Theratechnologies Inc. (THTX)
USD 2.77
(-5.14%)
USD 2.77
(-5.14%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -10.62 Million USD | 73.37% |
| 2022 | -39.9 Million USD | -58.14% |
| 2021 | -25.23 Million USD | -40.54% |
| 2020 | -17.95 Million USD | -110.94% |
| 2019 | -8.51 Million USD | -149.5% |
| 2018 | -3.41 Million USD | 60.34% |
| 2017 | -8.6 Million USD | -393.37% |
| 2016 | 2.93 Million USD | -5.71% |
| 2015 | 3.1 Million USD | 140.51% |
| 2014 | -7.67 Million USD | -7.06% |
| 2013 | -7.17 Million USD | -71.88% |
| 2012 | -4.17 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 4.33 Million USD | 295.06% |
| 2024 Q1 | -2.22 Million USD | -183.29% |
| 2024 Q3 | 6.21 Million USD | 43.23% |
| 2023 Q1 | -5.4 Million USD | 5.27% |
| 2023 Q4 | 2.67 Million USD | 4844.44% |
| 2023 Q2 | -7.94 Million USD | -46.92% |
| 2023 FY | -10.62 Million USD | 73.37% |
| 2023 Q3 | 54 Thousand USD | 100.68% |
| 2022 Q4 | -5.7 Million USD | -3.42% |
| 2022 Q2 | -20.96 Million USD | -171.52% |
| 2022 FY | -39.9 Million USD | -58.14% |
| 2022 Q1 | -7.72 Million USD | 4.28% |
| 2022 Q3 | -5.51 Million USD | 73.67% |
| 2021 Q1 | -4.58 Million USD | -11.56% |
| 2021 Q3 | -7.23 Million USD | -35.32% |
| 2021 FY | -25.23 Million USD | -40.54% |
| 2021 Q2 | -5.34 Million USD | -16.69% |
| 2021 Q4 | -8.06 Million USD | -11.43% |
| 2020 Q3 | -5.96 Million USD | -33.03% |
| 2020 FY | -17.95 Million USD | -110.94% |
| 2020 Q1 | -3.39 Million USD | 37.15% |
| 2020 Q2 | -4.48 Million USD | -32.28% |
| 2020 Q4 | -4.1 Million USD | 31.16% |
| 2019 Q2 | -2.01 Million USD | -338.48% |
| 2019 Q4 | -5.39 Million USD | -744.6% |
| 2019 FY | -8.51 Million USD | -149.5% |
| 2019 Q1 | -460 Thousand USD | -747.89% |
| 2019 Q3 | -639 Thousand USD | 68.32% |
| 2018 Q3 | 85 Thousand USD | 104.98% |
| 2018 Q2 | -1.7 Million USD | 15.17% |
| 2018 Q1 | -2.01 Million USD | 27.87% |
| 2018 FY | -3.41 Million USD | 60.34% |
| 2018 Q4 | 71 Thousand USD | -16.47% |
| 2017 Q4 | -2.78 Million USD | -20.18% |
| 2017 Q2 | -3.38 Million USD | -12376.49% |
| 2017 Q1 | -27.1 Thousand USD | -101.74% |
| 2017 FY | -8.6 Million USD | -393.37% |
| 2017 Q3 | -2.31 Million USD | 31.4% |
| 2016 Q3 | 416.3 Thousand USD | -31.33% |
| 2016 Q2 | 606.27 Thousand USD | 62.78% |
| 2016 Q4 | 1.55 Million USD | 274.54% |
| 2016 Q1 | 372.45 Thousand USD | -65.02% |
| 2016 FY | 2.93 Million USD | -5.71% |
| 2015 FY | 3.1 Million USD | 140.51% |
| 2015 Q4 | 1.06 Million USD | -30.4% |
| 2015 Q1 | -580.22 Thousand USD | 68.96% |
| 2015 Q3 | 1.52 Million USD | 34.27% |
| 2015 Q2 | 1.13 Million USD | 296.33% |
| 2014 Q1 | -3.24 Million USD | -26.55% |
| 2014 Q2 | 782.77 Thousand USD | 124.11% |
| 2014 Q3 | -3.57 Million USD | -556.31% |
| 2014 Q4 | -1.86 Million USD | 47.67% |
| 2014 FY | -7.67 Million USD | -7.06% |
| 2013 Q3 | -1.91 Million USD | -32.3% |
| 2013 Q2 | -1.45 Million USD | -10.22% |
| 2013 FY | -7.17 Million USD | -71.88% |
| 2013 Q1 | -1.31 Million USD | -13171.24% |
| 2013 Q4 | -2.56 Million USD | -33.71% |
| 2012 Q1 | -7.86 Million USD | -692.46% |
| 2012 Q4 | 10.06 Thousand USD | 101.12% |
| 2012 Q2 | -1.56 Million USD | 80.12% |
| 2012 Q3 | -902.27 Thousand USD | 42.32% |
| 2012 FY | -4.17 Million USD | 0.0% |
| 2011 Q2 | -6.56 Million USD | -11.46% |
| 2011 Q4 | -992.78 Thousand USD | 79.07% |
| 2011 Q1 | -5.89 Million USD | -126.8% |
| 2011 Q3 | -4.74 Million USD | 27.76% |
| 2010 Q3 | -3.56 Million USD | 27.46% |
| 2010 Q2 | -4.91 Million USD | -8.26% |
| 2010 Q1 | -4.53 Million USD | 4.99% |
| 2010 Q4 | 21.98 Million USD | 716.78% |
| 2009 Q3 | 5.31 Million USD | 201.01% |
| 2009 Q1 | -8.47 Million USD | -14.39% |
| 2009 Q2 | -5.26 Million USD | 37.85% |
| 2009 Q4 | -4.77 Million USD | -189.85% |
| 2008 Q3 | -10.56 Million USD | 7.73% |
| 2008 Q1 | -11.08 Million USD | 2.21% |
| 2008 Q2 | -11.44 Million USD | -3.27% |
| 2008 Q4 | -7.4 Million USD | 29.89% |
| 2007 Q2 | -7.52 Million USD | 6.63% |
| 2007 Q3 | -9.62 Million USD | -27.79% |
| 2007 Q1 | -8.06 Million USD | -45.56% |
| 2007 Q4 | -11.33 Million USD | -17.8% |
| 2006 Q3 | -6.55 Million USD | -16.1% |
| 2006 Q1 | -4.78 Million USD | -0.37% |
| 2006 Q2 | -5.65 Million USD | -18.03% |
| 2006 Q4 | -5.54 Million USD | 15.54% |
| 2005 Q1 | 8.44 Million USD | 256.8% |
| 2005 Q3 | -4.26 Million USD | 5.64% |
| 2005 Q4 | -4.76 Million USD | -11.85% |
| 2005 Q2 | -4.51 Million USD | -153.52% |
| 2004 Q3 | -3.26 Million USD | 39.99% |
| 2004 Q1 | -5.31 Million USD | 69.52% |
| 2004 Q2 | -5.44 Million USD | -2.41% |
| 2004 Q4 | -5.38 Million USD | -64.81% |
| 2003 Q3 | -4.83 Million USD | 19.5% |
| 2003 Q4 | -17.44 Million USD | -260.61% |
| 2003 Q2 | -6 Million USD | -70.69% |
| 2003 Q1 | -3.51 Million USD | 35.79% |
| 2002 Q4 | -5.48 Million USD | -36.93% |
| 2002 Q1 | -4.88 Million USD | -521.39% |
| 2002 Q2 | -4.17 Million USD | 14.43% |
| 2002 Q3 | -4 Million USD | 4.22% |
| 2001 Q1 | -2.3 Million USD | -14.91% |
| 2001 Q4 | -786.02 Thousand USD | 75.72% |
| 2001 Q3 | -3.23 Million USD | -34.5% |
| 2001 Q2 | -2.4 Million USD | -4.37% |
| 2000 Q1 | -1.3 Million USD | 1.57% |
| 2000 Q2 | -1.66 Million USD | -27.43% |
| 2000 Q3 | -1.36 Million USD | 18.09% |
| 2000 Q4 | -2 Million USD | -46.81% |
| 1999 Q4 | -1.33 Million USD | -32.55% |
| 1999 Q3 | -1 Million USD | 7.51% |
| 1999 Q1 | -795.49 Thousand USD | -17.75% |
| 1999 Q2 | -1.08 Million USD | -36.41% |
| 1998 Q3 | -1.07 Million USD | 12.95% |
| 1998 Q4 | -675.56 Thousand USD | 37.2% |
| 1998 Q1 | -1.12 Million USD | -35.85% |
| 1998 Q2 | -1.23 Million USD | -9.92% |
| 1997 Q1 | -1.02 Million USD | 0.0% |
| 1997 Q4 | -827.55 Thousand USD | 23.37% |
| 1997 Q2 | -1.37 Million USD | -34.77% |
| 1997 Q3 | -1.07 Million USD | 21.67% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Esperion Therapeutics, Inc. | -155.56 Million USD | 93.169% |
| Safety Shot Inc | -12.18 Million USD | 12.78% |
| Cosmos Health Inc. | -21.83 Million USD | 51.322% |
| Cronos Group Inc. | -81.37 Million USD | 86.941% |
| Ironwood Pharmaceuticals, Inc. | 209.03 Million USD | 105.084% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | 72.858% |
| Organogenesis Holdings Inc. | 12.52 Million USD | 184.846% |
| Universe Pharmaceuticals INC | -3.52 Million USD | -201.324% |
| ProPhase Labs, Inc. | -21.61 Million USD | 50.831% |
| Sonoma Pharmaceuticals, Inc. | -4.7 Million USD | -126.058% |
| Dynavax Technologies Corporation | -37.02 Million USD | 71.3% |
| Radius Health, Inc. | -3.92 Million USD | -170.752% |
| China SXT Pharmaceuticals, Inc. | -2.51 Million USD | -322.508% |
| Alvotech | -354.86 Million USD | 97.005% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | -122.076% |
| Alpha Teknova, Inc. | -35.56 Million USD | 70.118% |
| Intra-Cellular Therapies, Inc. | -159.38 Million USD | 93.332% |
| SCYNEXIS, Inc. | 72.66 Million USD | 114.624% |
| Harrow Health, Inc. | 580 Thousand USD | 1932.241% |
| Biofrontera Inc. | -22.67 Million USD | 53.138% |
| DURECT Corporation | -36.88 Million USD | 71.188% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | -101.689% |
| ANI Pharmaceuticals, Inc. | 46.97 Million USD | 122.625% |
| OptiNose, Inc. | -22.74 Million USD | 53.284% |
| RedHill Biopharma Ltd. | 12.63 Million USD | 184.128% |
| Aquestive Therapeutics, Inc. | -15.1 Million USD | 29.632% |
| Cumberland Pharmaceuticals Inc. | -6.21 Million USD | -71.105% |
| SIGA Technologies, Inc. | 83.62 Million USD | 112.709% |
| Lifecore Biomedical, Inc. | 9.33 Million USD | 213.889% |
| Shineco, Inc. | -17.06 Million USD | 37.73% |
| Phibro Animal Health Corporation | 53.31 Million USD | 119.932% |
| Procaps Group S.A. | 52.32 Million USD | 120.31% |
| TherapeuticsMD, Inc. | -8.52 Million USD | -24.686% |
| Regencell Bioscience Holdings Limited | -4.73 Million USD | -124.353% |
| Viatris Inc. | 766.2 Million USD | 101.387% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | -122.076% |
| Rockwell Medical, Inc. | -6.67 Million USD | -59.325% |
| Incannex Healthcare Limited | -30.04 Million USD | 64.625% |
| Aytu BioPharma, Inc. | -5.25 Million USD | -102.265% |
| Tilray Brands, Inc. | -174.74 Million USD | 93.919% |
| Collegium Pharmaceutical, Inc. | 166.96 Million USD | 106.365% |
| PetIQ, Inc. | 60.01 Million USD | 117.707% |
| Silver Spike Investment Corp. | 7.34 Million USD | 244.78% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 104.236% |
| Journey Medical Corporation | -2.07 Million USD | -412.639% |
| Alimera Sciences, Inc. | -1.47 Million USD | -622.434% |
| Petros Pharmaceuticals, Inc. | -13.61 Million USD | 21.96% |
| Assertio Holdings, Inc. | -243.53 Million USD | 95.636% |
| Shuttle Pharmaceuticals Holdings, Inc. | -5.89 Million USD | -80.352% |
| Embecta Corp. | 221.5 Million USD | 104.798% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 46.998% |
| Procaps Group, S.A. | 38.97 Million USD | 127.268% |
| PainReform Ltd. | -9.58 Million USD | -10.883% |
| Avadel Pharmaceuticals plc | -137.84 Million USD | 92.291% |
| Hempacco Co., Inc. | -8.81 Million USD | -20.593% |
| Talphera, Inc. | -16.88 Million USD | 37.077% |
| Pacira BioSciences, Inc. | 87.67 Million USD | 112.121% |
| Alvotech | -354.86 Million USD | 97.005% |
| Lantheus Holdings, Inc. | 364.64 Million USD | 102.914% |
| Kamada Ltd. | 10.06 Million USD | 205.594% |
| Indivior PLC | -4 Million USD | -165.675% |
| Currenc Group, Inc. | -6.64 Million USD | -59.906% |
| Evoke Pharma, Inc. | -7.43 Million USD | -43.011% |
| Flora Growth Corp. | -50.35 Million USD | 78.895% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 46.998% |
| Evolus, Inc. | -49.23 Million USD | 78.415% |
| HUTCHMED (China) Limited | 18.37 Million USD | 157.834% |
| Amphastar Pharmaceuticals, Inc. | 196.98 Million USD | 105.395% |
| Akanda Corp. | -10.05 Million USD | -5.727% |